DNA Damage Repair Deficiency in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer, especially aggressive forms, benefits from molecular-targeted therapies and biomarker-based treatment stratification.
• Deficiencies in DNA damage repair (DDR) pathways are frequent in prostate cancer.
• Emerging research highlights the links between DDR, androgen receptor (AR) signaling, and immune responses in prostate cancer.

Purpose of the Study:

• To review recent preclinical and early clinical findings on leveraging DDR defects in prostate cancer.
• To explore the potential of DDR defects as predictive biomarkers and therapeutic targets.

Main Methods:

• Review of preclinical studies.
• Analysis of early clinical trial data.
• Examination of molecular mechanisms linking DDR, AR signaling, and immunity.

Main Results:

• DDR defects are implicated in prostate cancer development and response to therapy.
• Exploiting DDR deficiencies shows promise for both diagnostic and therapeutic applications.
• Interconnections between DDR, AR signaling, and immune response are increasingly understood.

Conclusions:

• Targeting DDR defects represents a promising strategy for prostate cancer treatment.
• DDR deficiency detection is crucial for personalized medicine approaches in prostate cancer.
• Further research into DDR pathways can unlock novel therapeutic avenues for prostate cancer patients.